Singulex
About
Singulex develops direct molecular detection technology, cardiovascular monitoring, and related solutions to understand and manage diseases.
- 101 - 250
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $9.35M
- Industries
- Biotechnology,Health Care,Life Science,Medical
- Founded date
- Jan 1, 2003
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Singulex, Inc., a biotechnology company, develops and commercializes direct molecular detection technology solutions. Its solutions enable life science researchers and clinicians to understand and manage disease. The company develops biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers. It is conducting pilot studies to validate Erenna BioAssay System, a digital molecule detection platform, which detects and quantifies molecule biomarkers in clinical samples. The company also offers various custom assay services, such as pilot study services, assay prototyping, assay characterization, and assay validation. The company was formerly known as BioProfile Corporation and changed its name to Singulex, Inc in September 2003. Singulex is based in Hayward, California
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 7, 2007 | Series D | $19M | 1 | — | — | Detail |
| Jul 17, 2006 | Series C | $9.35M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Advantage Capital
|
— | Series D |
